Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share News

Daiichi and AstraZeneca cancer drugs secure further approvals in Japan

16th Sep 2026 09:46

(Alliance News) - Daiichi Sankyo Co Ltd on Wednesday said that its breast cancer drugs, Enhertu and Datroway, which are being developed in partnership with AstraZeneca PLC, have been approved for new indications in Japan. Read More

LONDON BROKER RATINGS: Oddo BHF cuts Safestore to neutral, cuts target

16th Sep 2026 09:16

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More

LONDON BRIEFING: UK inflation rises; Barratt cuts completions outlook

16th Sep 2026 07:59

(Alliance News) - UK inflation accelerates to 3.1% in August as higher fuel costs drive prices higher. Barratt Redrow reports a rise in annual pretax profit but lowers its home completions guidance, while Babcock says trading is in line with expectations and leaves its outlook unchanged. Read More

IN BRIEF: AstraZeneca Chair Demare acquires 2,500 shares

15th Sep 2026 18:27

AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Non-Executive Chair Michel Demare buys 2,500 shares at 12,121.33 pence each, for GBP303,033 in total, on Monday in London. Read More

LONDON BROKER RATINGS: Berenberg likes GSK; Deutsche Bank lifts Astra

15th Sep 2026 09:53

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More

LONDON MARKET CLOSE: FTSE 100 outperforms as AI worry hits Wall Street

14th Sep 2026 17:10

(Alliance News) - Stock prices in London closed mixed on Monday, with Middle East tensions, AI slowdown fears and caution ahead of a flurry of central bank meetings keeping investors on their toes. Read More

AstraZeneca, Daiichi report Enhertu benefit in advanced lung cancer

14th Sep 2026 03:47

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday reported their medicine Enhertu kept the disease from worsening for longer in patients with advanced lung cancer driven by a mutation in the gene that produces the human epidermal growth factor receptor 2. Read More

LONDON BROKER RATINGS: RBC prefers Astra to GSK; HSBC cuts Burberry

9th Sep 2026 09:04

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More

AstraZeneca hails tozorakimab licence application approval in US

8th Sep 2026 14:21

(Alliance News) - AstraZeneca PLC on Tuesday said its biologics licence application for tozorakimab in the US was accepted under priority review. Read More

LONDON BROKER RATINGS: Jefferies raises Autotrader and Rightmove

8th Sep 2026 09:08

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More

IN BRIEF: AstraZeneca wins US nod for Etcamah breast cancer combo

7th Sep 2026 01:08

AstraZeneca PLC - Cambridge, England-based pharmaceuticals firm - Welcomes the US Food & Drug Administration's accelerated approval of Etcamah for use alongside a cyclin‑dependent kinase 4 and 6 inhibitor, a type of medicine that slows cancer cell growth, in adults with advanced hormone‑driven breast cancer. Says Etcamah, which blocks the effect of estrogen on tumour cells, is cleared for patients who develop a mutation in the estrogen receptor 1 gene, a change that can make standard hormone treatment stop working. AstraZeneca says the decision is supported by Serena-6 phase three trial showing the combination keeps the disease from worsening for longer than current first‑line therapy. The firm adds that safety findings are in line with what is already known about the medicines used. Etcamah is also approved in more than 30 countries. Read More

IN BRIEF: Hutchmed "thrilled" by positive phase 3 trial results

1st Sep 2026 13:37

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Announces "positive high-level results" from the Sanovo China phase 3 trial of Orpathys plus Tagrisso in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer, whose tumours harbour epidermal growth factor receptor mutation and MET overexpression. Orpathys, or savolitinib, combined with Tagrisso or osimertinib, showed "a statistically significant and highly clinically meaningful improvement in progression-free survival" in the high MET and intention-to-treat patient populations, compared with Tagrisso alone. Hutchmed adds that "the combination also demonstrated a very encouraging clinical benefit in [the secondary endpoint of] overall survival" in both populations. Hutchmed is jointly developing Orpathys with AstraZeneca, which is also commercialising the treatment. Read More

UK dividends calendar - next 7 days

1st Sep 2026 13:35

Read More

AstraZeneca unveils Zegfrovy deal, lung trial win and Enhertu approval

1st Sep 2026 11:56

(Alliance News) - AstraZeneca PLC on Tuesday announced positive developments across its oncology portfolio, including a new lung-cancer licensing deal, positive trial results and EU approval for Enhertu breast-cancer treatment. Read More

WINNERS & LOSERS: Oil majors rise, miners slide on lower metals prices

1st Sep 2026 10:35

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More

LONDON BRIEFING: UK house prices subdued; Bunzl lifts outlook

1st Sep 2026 07:58

(Alliance News) - UK house price growth remains subdued in August despite a modest monthly recovery. Bunzl upgrades its full-year outlook and announces a GBP500 million share buyback, while Bodycote and Gamma Communications accept takeover offers. Read More

AstraZeneca and Amgen announce positive Tezspire trial results in EoE

27th Aug 2026 08:35

(Alliance News) - AstraZeneca PLC and Amgen Inc on Thursday announced positive top-line results from the phase 3 Crossing trial of tezepelumab in patients living with eosinophilic esophagitis. Read More

LONDON BRIEFING: PPHE Hotel Group swings to half-year profit

27th Aug 2026 08:00

(Alliance News) - on Thursday, as markets await the imminent start of the Jackson Hole summit and Federal Reserve Chair Kevin Warsh's Friday speech. Read More

IN BRIEF: Daiichi Sankyo, AstraZeneca start phase 3 Datroway trial

26th Aug 2026 17:17

Daiichi Sankyo Co Ltd and AstraZeneca PLC - pharmaceutical companies based in Tokyo and Cambridge, respectively - The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway, generic name datopotamab deruxtecan, plus either AstraZeneca's rilvegostomig or Datroway monotherapy versus current standard of care as an adjuvant treatment. Patients under study are diagnosed with muscle-invasive urothelial cancer at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. Datroway was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca. The partners are also evaluating Datroway plus platinum-based chemotherapy compared to gemcitabine and platinum-based chemotherapy in patients with metastatic urothelial carcinoma following progression during or after treatment with enfortumab vedotin in combination with pembrolizumab in the TROPION-Urothelial03 phase 2/3 trial. Read More

LONDON MARKET CLOSE: FTSE 100 drifts lower as eyes turn to Nvidia

26th Aug 2026 17:02

(Alliance News) - London's FTSE 100 faded into the close on Wednesday, posting modest losses, as a strong US inflation print knocked sentiment ahead of Nvidia earnings. Read More

FTSE 100 Latest
Value10,506.58
Change-44.59